[A26-83] Abemaciclib (breast cancer; adjuvant treatment) –Addendum to Project A26-17
Last updated 20.08.2026
Project no.:
A26-83
Commission:
Commission awarded on 08.07.2026 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adjuvant treatment of patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive early breast cancer at high risk of recurrence
Result of dossier assessment:
- Premenopausal women: unchanged after addendum: added benefit not proven
- Postmenopausal women: unchanged after addendum: added benefit not proven
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
DOI:
https://doi.org/10.60584/A26-83
| Project no. | Title | Status |
|---|---|---|
| A26-17 | Abemaciclib (breast cancer; adjuvant treatment) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
20-08-2026 A G-BA decision was published.
G-BA documents on this decision